

## HR 1425

Patient Protection and Affordable Care Enhancement Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 28, 2019

**Current Status:** Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 523.

**Latest Action:** Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 523.  
(Sep 8, 2020)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/1425>

### Sponsor

---

**Name:** Rep. Craig, Angie [D-MN-2]

**Party:** Democratic • **State:** MN • **Chamber:** House

## Cosponsors (61 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Peters, Scott H. [D-CA-52]	D · CA		Feb 28, 2019
Rep. Underwood, Lauren [D-IL-14]	D · IL		Mar 4, 2019
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Mar 5, 2019
Rep. Schrader, Kurt [D-OR-5]	D · OR		Mar 5, 2019
Rep. Carbajal, Salud O. [D-CA-24]	D · CA		Mar 7, 2019
Rep. Lipinski, Daniel [D-IL-3]	D · IL		Mar 7, 2019
Rep. Heck, Denny [D-WA-10]	D · WA		Mar 11, 2019
Rep. Brownley, Julia [D-CA-26]	D · CA		Mar 12, 2019
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Mar 12, 2019
Rep. Himes, James A. [D-CT-4]	D · CT		Mar 18, 2019
Rep. Allred, Colin Z. [D-TX-32]	D · TX		Mar 25, 2019
Rep. Bera, Ami [D-CA-7]	D · CA		Mar 25, 2019
Rep. Blunt Rochester, Lisa [D-DE-At Large]	D · DE		Mar 25, 2019
Rep. Bustos, Cheri [D-IL-17]	D · IL		Mar 25, 2019
Rep. Cisneros, Gilbert Ray, Jr. [D-CA-39]	D · CA		Mar 25, 2019
Rep. Hill, Katie [D-CA-25]	D · CA		Mar 25, 2019
Rep. Lee, Susie [D-NV-3]	D · NV		Mar 25, 2019
Rep. Lujan, Ben Ray [D-NM-3]	D · NM		Mar 25, 2019
Rep. Rose, Max [D-NY-11]	D · NY		Mar 25, 2019
Rep. Rouda, Harley [D-CA-48]	D · CA		Mar 25, 2019
Rep. Schrier, Kim [D-WA-8]	D · WA		Mar 25, 2019
Rep. Trone, David J. [D-MD-6]	D · MD		Mar 25, 2019
Rep. Costa, Jim [D-CA-16]	D · CA		Mar 26, 2019
Rep. Dingell, Debbie [D-MI-12]	D · MI		Mar 26, 2019
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		Mar 26, 2019
Rep. Finkenauer, Abby [D-IA-1]	D · IA		Mar 26, 2019
Rep. Kennedy, Joseph P., III [D-MA-4]	D · MA		Mar 26, 2019
Rep. Larsen, Rick [D-WA-2]	D · WA		Mar 26, 2019
Rep. Pallone, Frank, Jr. [D-NJ-6]	D · NJ		Mar 26, 2019
Rep. Ruiz, Raul [D-CA-36]	D · CA		Mar 26, 2019
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Mar 26, 2019
Rep. Schiff, Adam B. [D-CA-28]	D · CA		Mar 26, 2019
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Mar 27, 2019
Rep. Phillips, Dean [D-MN-3]	D · MN		Mar 27, 2019
Rep. Spanberger, Abigail Davis [D-VA-7]	D · VA		Mar 27, 2019
Rep. Van Drew, Jefferson [D-NJ-2]	D · NJ		Mar 28, 2019
Rep. Brindisi, Anthony [D-NY-22]	D · NY		Apr 2, 2019
Rep. Case, Ed [D-HI-1]	D · HI		Apr 2, 2019
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		Apr 2, 2019
Rep. McCollum, Betty [D-MN-4]	D · MN		Apr 8, 2019
Rep. Neguse, Joe [D-CO-2]	D · CO		Apr 8, 2019

Cosponsor	Party / State	Role	Date Joined
Rep. McAdams, Ben [D-UT-4]	D · UT		Apr 25, 2019
Rep. Moore, Gwen [D-WI-4]	D · WI		Apr 25, 2019
Rep. Kilmer, Derek [D-WA-6]	D · WA		Apr 29, 2019
Rep. Mucarsel-Powell, Debbie [D-FL-26]	D · FL		Apr 29, 2019
Rep. Stevens, Haley M. [D-MI-11]	D · MI		Apr 29, 2019
Rep. Barragan, Nanette Diaz [D-CA-44]	D · CA		May 30, 2019
Rep. Kelly, Robin L. [D-IL-2]	D · IL		May 30, 2019
Rep. Tonko, Paul [D-NY-20]	D · NY		May 30, 2019
Rep. Cárdenas, Tony [D-CA-29]	D · CA		Jun 10, 2019
Rep. Welch, Peter [D-VT-At Large]	D · VT		Jun 10, 2019
Rep. Raskin, Jamie [D-MD-8]	D · MD		Jun 20, 2019
Rep. Lofgren, Zoe [D-CA-19]	D · CA		Jul 2, 2019
Rep. Davids, Sharice [D-KS-3]	D · KS		Sep 9, 2019
Rep. Luria, Elaine G. [D-VA-2]	D · VA		Sep 18, 2019
Rep. Fortenberry, Jeff [R-NE-1]	R · NE		Oct 16, 2019
Rep. Kirkpatrick, Ann [D-AZ-2]	D · AZ		Nov 18, 2019
Rep. Rice, Kathleen M. [D-NY-4]	D · NY		Nov 19, 2019
Rep. Wexton, Jennifer [D-VA-10]	D · VA		Nov 22, 2019
Rep. Connolly, Gerald E. [D-VA-11]	D · VA		Jan 24, 2020
Rep. Speier, Jackie [D-CA-14]	D · CA		Jan 24, 2020

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	Mar 27, 2019

### Subjects & Policy Tags

#### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
116 S 4521	Related bill	<b>Aug 11, 2020:</b> Read twice and referred to the Committee on Finance.
116 HRES 1017	Related bill	<b>Jun 25, 2020:</b> Motion to reconsider laid on the table Agreed to without objection.
116 HR 6130	Related bill	<b>Mar 9, 2020:</b> Referred to the House Committee on Education and Labor.
116 HR 6135	Related bill	<b>Mar 9, 2020:</b> Referred to the House Committee on Energy and Commerce.
116 HR 6136	Related bill	<b>Mar 9, 2020:</b> Referred to the House Committee on Energy and Commerce.
116 HR 6149	Related bill	<b>Mar 9, 2020:</b> Referred to the House Committee on Energy and Commerce.
116 HR 6151	Related bill	<b>Mar 9, 2020:</b> Referred to the House Committee on Energy and Commerce.
116 HR 5291	Related bill	<b>Dec 4, 2019:</b> Referred to the Subcommittee on Health.
116 HR 4821	Related bill	<b>Oct 26, 2019:</b> Referred to the Subcommittee on Health.
116 S 2218	Related bill	<b>Jul 23, 2019:</b> Read twice and referred to the Committee on Finance.
116 S 1905	Related bill	<b>Jun 19, 2019:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
116 HR 987	Related bill	<b>May 20, 2019:</b> Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
116 HR 986	Related bill	<b>May 15, 2019:</b> Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 90.
116 S 1400	Related bill	<b>May 9, 2019:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
116 HR 1385	Related bill	<b>May 3, 2019:</b> Placed on the Union Calendar, Calendar No. 27.
116 HR 1386	Related bill	<b>May 3, 2019:</b> Placed on the Union Calendar, Calendar No. 28.
116 HR 1879	Related bill	<b>Mar 27, 2019:</b> Referred to the Subcommittee on Health.
116 HR 1884	Related bill	<b>Mar 27, 2019:</b> Referred to the Subcommittee on Health.
116 HR 1870	Related bill	<b>Mar 26, 2019:</b> Referred to the House Committee on Ways and Means.
116 S 585	Related bill	<b>Feb 27, 2019:</b> Read twice and referred to the Committee on Finance.
116 S 455	Related bill	<b>Feb 12, 2019:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
116 HR 584	Related bill	<b>Jan 25, 2019:</b> Referred to the Subcommittee on Health.

## **Patient Protection and Affordable Care Enhancement Act**

This bill modifies various health insurance programs related to consumer costs for private health insurance plans, Medicaid funding and eligibility, and prescription drug pricing. Specifically, the bill increases the amount and income thresholds for the premium assistance tax credit program and expands access to such tax credit for employees with employer-provided family plans that cost in excess of 9.5% of the employee's household income.

Further, the bill provides additional funding for states to establish health insurance exchanges and establishes the Improve Health Insurance Affordability Fund. States must use allocated funds to (1) issue reinsurance payments to health insurers (i.e., reimbursements to protect insurers against exceedingly high claims) for individual health insurance coverage, or (2) provide other assistance to reduce out-of-pocket costs (e.g., copayments, coinsurance, and deductibles) for qualified health plans offered in the individual market through an exchange.

The bill also nullifies a rule that expands short-term, limited-duration health insurance plans. Such plans may offer coverage for only a limited amount of time and are exempt from certain coverage requirements. The bill also nullifies guidance that alters how states may satisfy the criteria for approval of State Innovation Waivers from certain health insurance coverage requirements.

Additionally, the bill directs the Department of Health and Human Services (HHS) to conduct outreach, education, and reporting activities related to enrollment in plans through health insurance exchanges, particularly in areas with disparities in income or health outcomes. It also establishes and funds grants to states to promote enrollment in health insurance coverage and requires health insurance exchanges to establish network adequacy standards. The bill makes recipients of benefits under the Deferred Action for Childhood Arrivals Program eligible for qualified health plans offered through such exchanges.

With respect to Medicaid, the bill increases to 100% the federal share of the cost for states to meet the minimum Medicaid expansion requirements and to cover newly-eligible individuals; the current federal share of such costs is 90%. It also requires states to provide 12 months of continuous coverage to individuals enrolling in Medicaid or the Children's Health Insurance Program (CHIP) and extends postpartum Medicaid and CHIP coverage to 12 months. The bill further reduces federal matching funds for administrative costs and expands reporting requirements for states that have not met specified Medicaid expansion requirements.

Additionally, the bill

- extends through FY2024 the minimum payment requirements for primary care services;
- permanently extends CHIP funding and eligibility, enrollment, and quality assurance provisions;
- increases the permissible family income threshold for children whom states may make eligible for Medicaid and CHIP;
- extends Medicaid coverage to residents of the Freely Associated States (i.e., Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau); and
- increases the federal medical assistance percentage for services provided through Indian Health Care Services.

The bill also establishes the Fair Drug Pricing Program that directs HHS to negotiate with manufacturers to set the price

for selected drugs and biological products. HHS must select certain drugs and biological products that are among the most costly based on spending under Medicare and enter a voluntary negotiation with manufacturers to establish a maximum price for each drug or product. The negotiation must consider, among other factors, the cost of research and development of the selected drug or biological product, the cost of production, national sales data, and information about alternative products.

The bill establishes an excise tax on manufacturers that do not comply with a negotiated fair price agreement in the amount of specified percentages of the sales of such drug or product. The bill also creates a fund to implement the Fair Drug Pricing Program.

## Actions Timeline

---

- **Sep 8, 2020:** Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 523.
- **Aug 13, 2020:** Read the first time. Placed on Senate Legislative Calendar under Read the First Time.
- **Jun 30, 2020:** Received in the Senate.
- **Jun 29, 2020:** Considered under the provisions of rule H. Res. 1017. (consideration: CR H2599-2644)
- **Jun 29, 2020:** Rule provides for consideration of H.R. 1425, H.R. 5332, H.R. 7120, H.R. 7301 and H.J. Res. 90. The resolution provides that the provisions of section 125(c) of the Uruguay Round Agreements Act shall not apply during the remainder of the 116th Congress and the resolution amends H.Res. 967, agreed to on May 15, 2020.
- **Jun 29, 2020:** DEBATE - The House proceeded with three hours of debate on H.R. 1425.
- **Jun 29, 2020:** The previous question was ordered pursuant to the rule.
- **Jun 29, 2020:** Mr. Walden moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H2642-2643)
- **Jun 29, 2020:** Floor summary: DEBATE - The House proceeded with 10 minutes of debate on the Walden motion to recommit with instructions. The instructions contained in the motion seek to require the bill to be reported back to the House with an amendment to prevent the bill from taking effect unless the Secretary of Health and Human Services certifies that no provision of the bill would adversely affect research related to any drug intended to treat or prevent the virus that causes COVID-19.
- **Jun 29, 2020:** The previous question on the motion to recommit with instructions was ordered without objection.
- **Jun 29, 2020:** POSTPONED PROCEEDINGS - At the conclusion of debate on the motion to recommit with instructions, the Chair put the question on the motion and by voice vote, announced that the yeas had prevailed. Mr. Walden demanded the yeas and nays and the Chair postponed further consideration on the motion to recommit until a time to be announced.
- **Jun 29, 2020:** Considered as unfinished business. (consideration: CR H2664-2665)
- **Jun 29, 2020:** On motion to recommit with instructions Failed by the Yeas and Nays: 187 - 223 (Roll no. 123).
- **Jun 29, 2020:** Passed/agreed to in House: On passage Passed by the Yeas and Nays: 234 - 179 (Roll no. 124).
- **Jun 29, 2020:** On passage Passed by the Yeas and Nays: 234 - 179 (Roll no. 124). (text: CR H2599-2614)
- **Jun 29, 2020:** Motion to reconsider laid on the table Agreed to without objection.
- **Jun 24, 2020:** Rules Committee Resolution H. Res. 1017 Reported to House. Rule provides for consideration of H.R. 1425, H.R. 5332, H.R. 7120, H.R. 7301 and H.J. Res. 90. The resolution provides that the provisions of section 125(c) of the Uruguay Round Agreements Act shall not apply during the remainder of the 116th Congress and the resolution amends H.Res. 967, agreed to on May 15, 2020.
- **Mar 9, 2020:** Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-414.
- **Mar 9, 2020:** Placed on the Union Calendar, Calendar No. 334.
- **Apr 4, 2019:** Ordered to be Reported (Amended) by the Yeas and Nays: 30 - 22.
- **Apr 3, 2019:** Committee Consideration and Mark-up Session Held.
- **Mar 27, 2019:** Subcommittee Consideration and Mark-up Session Held.
- **Mar 27, 2019:** Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 18 - 13 .
- **Mar 1, 2019:** Referred to the Subcommittee on Health.
- **Feb 28, 2019:** Introduced in House
- **Feb 28, 2019:** Referred to the House Committee on Energy and Commerce